KAT6B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21609251	0.59	16/20
SCHEMBL21609001	0.67	15/20
SCHEMBL21609075	0.63	15/20
SCHEMBL21596803	0.78	14/20
SCHEMBL21596870	0.60	14/20
SCHEMBL21609082	0.58	14/20
SCHEMBL21609172	0.52	14/20
SCHEMBL21596948	0.50	14/20
SCHEMBL21609034	0.66	13/20
SCHEMBL21596887	0.64	13/20
SCHEMBL21596789	0.63	13/20
SCHEMBL21609185	0.61	13/20
SCHEMBL21609240	0.59	13/20
SCHEMBL21596824	0.58	13/20
SCHEMBL21596865	0.57	13/20
SCHEMBL21596791	0.57	13/20
SCHEMBL21596777	0.57	13/20
SCHEMBL21609057	0.57	13/20
SCHEMBL21609112	0.57	13/20
SCHEMBL21609052	0.54	13/20

Clinical trials — most relevant to KAT6B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma	PHASE1	WITHDRAWN
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans	nan	ACTIVE_NOT_RECRUITING
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study	nan	NOT_YET_RECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Epigenetics in the Aging Process	nan	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Nutrigenomics: Personalizing Weight Loss for Obese Veterans	nan	COMPLETED
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KAT6B binder may also engage these)

Protein	Name	Similarity
Q8BZ21	—	1.000	Q8BZ21 →
KAT6A	Histone acetyltransferase KAT6A	1.000	landscape →
Q8BRB7	—	1.000	Q8BRB7 →
Q5SVQ0	—	0.999	Q5SVQ0 →
Q8BMD7	—	0.999	Q8BMD7 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.999	landscape →
Q5TKR9	—	0.998	Q5TKR9 →
Q8WML3	—	0.998	Q8WML3 →
Q9H329	—	0.998	Q9H329 →
E1C2V1	—	0.998	E1C2V1 →
Q08BS4	—	0.996	Q08BS4 →
Q9NRR4	—	0.996	Q9NRR4 →
A7MBB4	—	0.996	A7MBB4 →
Q8VDU5	—	0.996	Q8VDU5 →
G5EGA3	—	0.996	G5EGA3 →
KDM2B	Lysine-specific demethylase 2B	0.996	landscape →
Q6IVY4	—	0.995	Q6IVY4 →
SNRK	SNF-related serine/threonine-protein kinase	0.995	landscape →
Q5VW22	—	0.995	Q5VW22 →
PIK3C2A	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha	0.995	landscape →
G5EEC5	—	0.995	G5EEC5 →
F4JZ68	—	0.995	F4JZ68 →
Q66624	—	0.995	Q66624 →
Q9HCH5	—	0.995	Q9HCH5 →
Q9P2R6	—	0.995	Q9P2R6 →
P13864	—	0.995	P13864 →
Q8TDB6	—	0.995	Q8TDB6 →
Q5R978	—	0.995	Q5R978 →
Q5HZJ0	—	0.995	Q5HZJ0 →
Q52LR7	—	0.995	Q52LR7 →